Novartis’ breast cancer drug cuts risk of death by 19 percent after six years, data shows

LONDON: Swiss drugmaker Novartis’ drug Kisqali helped extend survival for women with a form of high-risk, early-stage breast cancer, cutting their risk of death by 19 percent…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.arabnews.com)